<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405805</url>
  </required_header>
  <id_info>
    <org_study_id>isppd2018</org_study_id>
    <nct_id>NCT03405805</nct_id>
  </id_info>
  <brief_title>Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules</brief_title>
  <official_title>The Establishment of Serotype-specific Immunological Memory Against Pneumococcus by a 3+1 Versus a 2+1 or 3+0 Infant PCV13 Vaccination Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aghia Sophia Children's Hospital of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aghia Sophia Children's Hospital of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the establishment of immunological memory between
      the 3 different infant vaccination schedules with the 13-valent pneumococcal conjugate
      vaccine (PCV13) currently in use. We aim to determine the optimal schedule for the
      establishment of antigen-specific memory B-cell pool, which may serve as a correlate for
      longevity of immunological memory against vaccine serotypes. Moreover, we will study the
      transcriptome profiles expressed by peripheral lymphocytes during each immune response in an
      attempt to reveal immunological mechanisms beyond the antibody and circulating B cells level.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immunoglobulin G (IgG) antibody serum titers (measured by ELISA)</measure>
    <time_frame>28 days post last vaccine dose</time_frame>
    <description>measurement of IgG antibody titers in serum pre- and post- last dose of PCV13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>switched immunoglobulin G (swIgG) B memory cell response (measured by flow cytometry)</measure>
    <time_frame>28 days post last vaccine dose</time_frame>
    <description>phenotype characterisation of swIgG memory B cells pre- and post- last dose of PCV13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>immunoglobulin M (IgM) B memory cell response (measured by flow cytometry)</measure>
    <time_frame>28 days post last vaccine dose</time_frame>
    <description>phenotype characterisation of IgM memory B cells pre- and post- last dose of PCV13</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transcriptional profile of Peripheral Blood Mononuclear Cells (PBMC) in response to PCV13 (measured by RNA-Sequencing)</measure>
    <time_frame>7 days post last vaccine dose</time_frame>
    <description>transcriptome analysis of PBMCs pre- and post last dose of PCV13 on a cohort of patients</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Immunogenicity, Vaccine</condition>
  <condition>Immunologic Memory</condition>
  <arm_group>
    <arm_group_label>3+1</arm_group_label>
    <description>Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3+0</arm_group_label>
    <description>Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2+1</arm_group_label>
    <description>Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine (PCV13)</intervention_name>
    <description>Vaccination with PCV13</description>
    <arm_group_label>3+1</arm_group_label>
    <arm_group_label>3+0</arm_group_label>
    <arm_group_label>2+1</arm_group_label>
    <other_name>Prevenar13</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy infants 2-15 months of age living in Athens, Greece
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-15 months of age

        Exclusion Criteria:

          -  previously recorded allergy to PCV

          -  intravenous immunoglobulin (IVIG) given within the previous 6 months

          -  primary or secondary immunodeficiency

          -  any chronic medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vana Spoulou, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>&quot;Aghia Sophia&quot; Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Tzovara, MD</last_name>
    <phone>0030 2107467620</phone>
    <email>itzovara@med.uoa.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>'Aghia Sophia' Children's Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vana Spoulou</last_name>
      <phone>00302107467620</phone>
    </contact>
    <investigator>
      <last_name>Irene Tzovara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioanna Papadatou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aghia Sophia Children's Hospital of Athens</investigator_affiliation>
    <investigator_full_name>Vana Spoulou</investigator_full_name>
    <investigator_title>Assistant Professor of Paediatrics</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

